Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print          Annual reports

Tuesday 04 August, 2020

AstraZeneca PLC

AstraZeneca prices a $3bn bond issue

RNS Number : 0063V
AstraZeneca PLC
04 August 2020

4 August 2020 07:00 BST


AstraZeneca prices a $3bn bond issue


AstraZeneca PLC announces that, on 3 August 2020, it priced a three tranche global bond offering totalling $3bn. The offering is expected to close on 6 August 2020, subject to customary closing conditions. AstraZeneca expects to use the net proceeds of the issue for general corporate purposes, which may include the refinancing of existing indebtedness. The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of the following three tranches:


· $1.2bn of fixed rate notes with a coupon of 0.700%, maturing 8 April 2026;

· $1.3bn of fixed rate notes with a coupon of 1.375%, maturing 6 August 2030; and

· $0.5bn of fixed rate notes with a coupon of 2.125%, maturing 6 August 2050.


BofA Securities, Inc., HSBC Securities (USA) Inc. and Mizuho Securities USA LLC acted as joint book-running managers on the transaction and Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley and Co. LLC acted as co-managers on the transaction. The notes will be issued under AstraZeneca's effective shelf registration statement on Form F-3, which AstraZeneca filed with the SEC on 8 November 2019. The offering is being made solely by means of the prospectus contained within that shelf-registration statement, along with a prospectus supplement forming part of the effective registration statement, which investors should read.


A copy of the prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting BofA Securities, Inc. at 1-800-294-1322, HSBC Securities (USA) Inc. at 1-866-811-8049, or Mizuho Securities USA LLC at 1-866-271-7403. Readers may also download these documents for free by visiting the Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system on the SEC website at .


This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.


The bond issuance does not impact the Company's financial guidance for 2020.


About AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow the Company on Twitter @AstraZeneca.


Cautionary Statements Regarding Forward-Looking Statements

This announcement contains certain forward-looking statements with respect to the operations, performance and financial condition of AstraZeneca. Although the Company believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this announcement and AstraZeneca undertakes no obligation to update these forward-looking statements.



For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.


Adrian Kemp
Company Secretary

AstraZeneca PLC









This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t